A group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in men with castration-resistant prostate cancer (CRPC) who have already failed chemotherapy.
The researchers evaluated 45 men who had initially responded to docetaxel therapy and then had disease progression. The prospective multicenter study was conducted between November 2005 and January 2009. The men in the study were retreated with docetaxel (chemotherapy).
The researchers used a primary endpoint of a biochemical response (biochemical partial response defined as >50% prostate-specific antigen